Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaohui Zeng

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Frontiers in Public Health|October 17, 2022
Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectivenessXiaohui Zeng, Zhen Zhou, Xia Luo, et al.
Medicine|August 16, 2019
Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic diseaseXiaohui Zeng, Liubao Peng, Chongqing Tan, et al.
Frontiers in Pharmacology|August 8, 2022
The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung CancerXia Luo, Zhen Zhou, Xiaohui Zeng, et al.
Translational Lung Cancer Research|October 21, 2024
Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysisZiying Zhao, Xiaohui Zeng, Zhen Zhou, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|November 17, 2004
Shamrock surfactants: synthesis and characterizationDavid A Jaeger, Xiaohui Zeng, Robert P Apkarian
Frontiers in Public Health|October 10, 2022
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in ChinaXia Luo, Zhen Zhou, Xiaohui Zeng, et al.
Plos One|May 13, 2026
Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspectiveChaohao Shi, Yang Wang, Chongqing Tan, et al.
Clinical Therapeutics|January 25, 2020
Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTORXiaohui Zeng, Liubao Peng, Ye Peng, et al.
Zhongguo Yi Liao Qi Xie Za Zhi = Chinese Journal of Medical Instrumentation|October 22, 2014
[Development of residual voltage testing equipment]Xiaohui Zeng, Mingjun Wu, Li Cao, et al.
Frontiers in Oncology|July 16, 2021
First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisQiao Liu, Xia Luo, Lidan Yi, et al.
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Frontiers in Public Health|October 17, 2022
Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectivenessXiaohui Zeng, Zhen Zhou, Xia Luo, et al.
Medicine|August 16, 2019
Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic diseaseXiaohui Zeng, Liubao Peng, Chongqing Tan, et al.
Frontiers in Pharmacology|August 8, 2022
The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung CancerXia Luo, Zhen Zhou, Xiaohui Zeng, et al.
Translational Lung Cancer Research|October 21, 2024
Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysisZiying Zhao, Xiaohui Zeng, Zhen Zhou, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|November 17, 2004
Shamrock surfactants: synthesis and characterizationDavid A Jaeger, Xiaohui Zeng, Robert P Apkarian
Frontiers in Public Health|October 10, 2022
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in ChinaXia Luo, Zhen Zhou, Xiaohui Zeng, et al.
Plos One|May 13, 2026
Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspectiveChaohao Shi, Yang Wang, Chongqing Tan, et al.
Clinical Therapeutics|January 25, 2020
Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTORXiaohui Zeng, Liubao Peng, Ye Peng, et al.
Zhongguo Yi Liao Qi Xie Za Zhi = Chinese Journal of Medical Instrumentation|October 22, 2014
[Development of residual voltage testing equipment]Xiaohui Zeng, Mingjun Wu, Li Cao, et al.
Frontiers in Oncology|July 16, 2021
First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisQiao Liu, Xia Luo, Lidan Yi, et al.
Pageof 13